Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
1.
J Viral Hepat ; 21(12): 921-4, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25040045

ABSTRACT

HDV infection still remains a serious public health problem in Amazonia. There are few data regarding the biomolecular aspects of HBV/HDV co-infection in this region. We studied 92 patients HBsAg(+) /anti-HDV IgG(+) followed at the Hepatitis Referral Centers of Porto Velho (RO), Rio Branco and Cruzeiro do Sul (AC), Brazil, from March 2006 to March 2007 for whom the HDV and/or the HBV genotype could be determined. The HDV genotype could be determined in 90 patients, while the HBV genotypes could be positively determined in 74. HBV subgenotype F2 is the most prevalent (40.2%), followed by the subgenotypes A1 (15.2%) and D3 (8.7%), while 16.4% were other subgenotypes or genotypes, 4.3% were discordant and 15.2% were unamplifiable. Surprisingly, HDV genotype 3 (HDV-3) was found in all of the HBV/HDV-infected patients that could be genotyped for HDV, confirming that HDV-3 can associate with non-F HBV genotypes. However, a HDV-3 mutant was found in 29.3% of patients and was more frequently associated with non-F HBV genotypes (P < 0.001) than were nonmutant strains, suggesting that the mutation may facilitate association of HDV-3 with non-F HBV genotypes.


Subject(s)
Coinfection/epidemiology , Hepatitis B virus/genetics , Hepatitis B/epidemiology , Hepatitis D/epidemiology , Hepatitis Delta Virus/genetics , Mutation , Brazil/epidemiology , Genotype , Hepatitis Antibodies/blood , Hepatitis B/complications , Hepatitis B Surface Antigens/blood , Hepatitis B virus/classification , Hepatitis D/complications , Hepatitis Delta Virus/classification , Humans , Immunoglobulin G/blood , Molecular Sequence Data , RNA, Viral/chemistry , RNA, Viral/genetics , Sequence Analysis, DNA
2.
J Viral Hepat ; 20(3): 209-18, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23383660

ABSTRACT

Genome diversity is a hallmark of hepatitis B virus (HBV), which allowed its classification into 10 genotypes (A-J) and numerous subgenotypes. Among them, Genotype D is currently segregated into eight subgenotypes (D1-D8). Here, we report the identification and characterization of a novel subgenotype within genotype D of HBV from chronic hepatitis B e antigen (HBeAg)-negative patients of Eastern India. Phylogenetic tree analysis based on complete genome sequences revealed that six of 39 HBV/D isolates formed a distinct cluster supported by high bootstrap value and had nucleotide divergence >4% relative to the known D subgenotypes (D1-D8), justifying their assignment into a new subgenotype (D9). By comparing the amino acid sequences of the four ORFs of HBV/D9 with D1-D8, 36 specific residues, including a unique one (E(112) in the core region), were identified that could be considered as a signature of D9. Further analysis by Simplot, BootScan and jpHMM demonstrated that D9 resulted from a discrete recombination with genotype C over the precore-core region. This type of recombination has not been described previously as all C/D recombinants reported so far possessed genotype C backbones with mosaic fragments derived from HBV/D. Interestingly, compared to other subgenotypes of HBV/D, D9 isolates had a higher frequency of mutations (A1762T and G1764A) in the basal core promoter region that had been implicated in the development of hepatocellular carcinoma. Further investigations are needed to determine the overall prevalence and clinical significance of these newly characterized D9 strains and to assess the impact of inter-genotypic recombination on viral properties.


Subject(s)
Hepatitis B e Antigens/blood , Hepatitis B virus/classification , Hepatitis B virus/isolation & purification , Hepatitis B, Chronic/virology , Recombination, Genetic , Adult , Aged , Cluster Analysis , DNA, Viral/genetics , Female , Genome, Viral , Genotype , Hepatitis B virus/genetics , Humans , India , Male , Middle Aged , Molecular Sequence Data , Phylogeny , Sequence Analysis, DNA , Sequence Homology , Young Adult
3.
J Viral Hepat ; 19(10): 744-53, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22967106

ABSTRACT

Hepatitis delta virus (HDV) coinfection or superinfection in hepatitis B virus (HBV)-infected patients results in a more aggressive liver disease, with more often fulminant forms and more rapid progression to cirrhosis and hepatocellular carcinoma. The mechanism(s) for this pejorative evolution remains unclear. To explore a specific HDV pathogenesis, we used a model of transient transfection of plasmids expressing the small (sHDAg or p24) or the large (LHDAg or p27) delta antigen in hepatocyte cell lines. We found that the production of reactive oxygen species was significantly higher in cells expressing p27. Consequently, p27 activated the signal transducer and activator of transcription-3 (STAT-3) and the nuclear factor kappa B (NF-κB) via the oxidative stress pathway. Moreover in the presence of antioxidants (PDTC, NAC) or calcium inhibitors (TMB-8, BAPTA-AM, Ruthenium Red), p27-induced activation of STAT-3 and NF-κB was dramatically reduced. Similarly, using a mutated form of p27, where the cysteine 211-isoprenylation residue was replaced by a serine, a significant reduction of STAT-3 and NF-κB activation was seen, suggesting the involvement of isoprenylation in this process. Additionally, we show that p27 is able to induce oxidative stress through activation of NADPH oxidase-4. These results provide insight into the mechanisms by which p27 can alter intracellular events relevant to HDV-related liver pathogenesis.


Subject(s)
Hepatitis Delta Virus/immunology , Hepatitis Delta Virus/pathogenicity , Hepatitis delta Antigens/immunology , NF-kappa B/biosynthesis , Oxidative Stress , STAT3 Transcription Factor/biosynthesis , Cell Line , Hepatocytes/immunology , Hepatocytes/virology , Humans
4.
Pathol Biol (Paris) ; 58(4): 245-53, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20580167

ABSTRACT

During the next few decades, vaccination against hepatitis B virus (HBV) will dramatically change the epidemiological profile of this worldwide infection especially when Heath Policies encourage including HBV vaccination program for the newborns. However, it is still estimated that more than 2000millions living people have met HBV. Symptomatic hepatitis with jaundice is less frequent than asymptomatic infection; however, as much as 350millions of individuals remain chronically infected by HBV. In these cases, the need for efficient antiviral therapy remains clear when a viral replication is observed to control the risk of progression and the need for liver transplantation, which represents the only end-stage treatment. Indeed, patients having chronic hepatitis B (CHB) can now be successfully treated using nucleos(t)ide analogs (NA) or pegylated interferon (PEG-IFN). Therefore, beside vaccination, prevention of the progression of the disease to cirrhosis and liver decompensation, leading to end-stage liver disease and/or to hepatocellular carcinoma, by inhibiting viral replication seems to represent the best approach to improve survival. At last but not least, co-morbidities and other viral infections, leading also to chronic liver cirrhosis or liver inflammation such as the specific satellite delta virus (HDV), human immunodeficency virus (HIV) and/or hepatitis C (HCV) virus, are able to accelerate the progression and have to be taken in account. Interestingly, in treated infection, the dogma of the irreversibility of the liver fibrosis, when the cirrhosis is constituted, is tumbling down. In this review, we will focus on the clinical, virological and therapeutic aspects of hepatitis B infection in order to expose the proposals to follow-up and treat HBV-infected patients and the prevention of drug-resistant HBV mutants that frequently arise, leading to treatment failure and progression to liver disease.


Subject(s)
Hepatitis B/diagnosis , Hepatitis B/therapy , Antiviral Agents/therapeutic use , Carcinoma, Hepatocellular/prevention & control , Carcinoma, Hepatocellular/virology , DNA, Viral/analysis , Drug Resistance, Viral , Genotype , Hepatitis B/prevention & control , Hepatitis B Vaccines , Hepatitis B virus/drug effects , Hepatitis B virus/genetics , Hepatitis B virus/growth & development , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/prevention & control , Hepatitis B, Chronic/therapy , Humans , Infant, Newborn , Liver Diseases/prevention & control , Liver Diseases/virology , Liver Neoplasms/prevention & control , Liver Neoplasms/virology , Mass Vaccination , Virus Replication
5.
Aliment Pharmacol Ther ; 26(10): 1437-46, 2007 Nov 15.
Article in English | MEDLINE | ID: mdl-17900267

ABSTRACT

BACKGROUND: We previously reported high prevalence of hepatitis C virus genotype 5a (HCV 5) (14%) in Central France. AIM: To identify the risk factors associated with HCV5 infection and to characterize local HCV5 lineages. METHOD: A case-control study and phylogenetic analysis were conducted. RESULTS: In all, 131 HCV5 and 343 HCV non 5 infected patients were enrolled. No HCV5 patient was born in sub-Saharan Africa and only two were injection drug user. HCV5 contamination was associated with living in a rural area called Vic le Comte (VLC) in non-transfused patients (OR = 17.7), with transfusion in patients living outside VLC (OR = 3.8) and with receiving injections in patients from VLC (OR = 3.1). More than 80% of the patients from outside VLC were contaminated by transfusion and those from VLC mainly by an iatrogenic factor - injections performed before 1972 by the local physician. Phylogenetic analysis of HCV5 isolates evidenced no distinct genetic cluster, but close relationships between the isolates of spouse pairs and between blood donors and recipients. CONCLUSIONS: Our results suggest that HCV5 spread in our district by iatrogenic route before 1972 and then via transfusion to the whole district. Collaborative studies are underway to study viral sequences from different parts of Africa and Europe to estimate the origin of our HCV 5a strains.


Subject(s)
Hepacivirus/metabolism , Hepatitis C/virology , Adult , Aged , Case-Control Studies , Female , France/epidemiology , Genotype , Hepatitis C/epidemiology , Hepatitis C/transmission , Hepatitis C Antibodies/analysis , Hepatitis C Antibodies/blood , Humans , Male , Middle Aged , Phylogeny , Prevalence , Reverse Transcriptase Polymerase Chain Reaction , Risk Factors
6.
J Viral Hepat ; 14(7): 460-7, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17576387

ABSTRACT

Hepatitis C virus genotype 4 (HCV-4) infection is progressing in Europe, where epidemiology and sustained virological response (SVR) seem to be different than in the Middle East. We analysed epidemiological features and SVR rates in a retrospective study of 1532 HCV-4-infected patients, including 1056 patients infected in France, 227 immigrants infected in Egypt and 249 in sub-Saharan Africa. SVR rates were assessed in 242 naive patients of the 1532, who received peginterferon plus ribavirin for 48 weeks. HCV subtype 4a or 4d was the most common among patients infected in France, where the predominant route of transmission was intravenous drug abuse. The 4a subtype was largely predominant (93%) among patients infected in Egypt, where transmission was mostly because of parenteral treatment for schistosomiasis. More than seven different subtypes and no predominant route of infection were found in patients infected in sub-Saharan Africa. Liver fibrosis was significantly less severe in patients infected in France and Africa than in patients infected in Egypt. SVR rates were higher in patients infected in Egypt, compared with those infected in France or Africa (54.9%, 40.3% and 32.4%, respectively, P < 0.05). An overall better response was observed in patients infected with the 4a subtype. In multivariate analysis, two factors were associated independently with SVR: the Egyptian origin of transmission and the absence of severe fibrosis. In conclusion, the distribution of HCV-4 subtypes varies with the geographical origin of transmission and affects the SVR following antiviral treatment.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/epidemiology , Interferon-alpha/therapeutic use , Ribavirin/therapeutic use , Adult , Africa South of the Sahara/epidemiology , Drug Therapy, Combination , Egypt/epidemiology , Female , France/epidemiology , Genotype , Hepacivirus/classification , Hepatitis C, Chronic/pathology , Hepatitis C, Chronic/virology , Humans , Interferon alpha-2 , Liver/pathology , Liver Cirrhosis/drug therapy , Liver Cirrhosis/epidemiology , Liver Cirrhosis/pathology , Liver Cirrhosis/virology , Male , Middle Aged , Polyethylene Glycols , Recombinant Proteins , Treatment Outcome
7.
J Viral Hepat ; 14(2): 96-106, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17244249

ABSTRACT

We investigated whether an HCV NS3 protease quasispecies heterogeneity was associated with progression from viral cirrhosis to hepatocellular carcinoma (HCC). The NS3 protease quasispecies structure of 10 HCV-1b cirrhotic patients (controls) was compared with that of 10 paired HCV-1b cirrhotic patients who displayed progression to HCC (cases). NS3 protease genetic complexity and diversity did not differ significantly between cases and controls. Amino acid substitutions were detected at 20 (11%) and 25 (14%) sites in at least two variants of the NS3 protease in cases and controls, respectively. Significant differences in the percentage of substituted clones were observed for 10 NS3 sites. Mutations Y56F, I71V, T72I, Q86P, P89S, S101G/D, R117H, S122G/T/N, V132I and V170I were more frequently observed in the NS3 protease sequences of controls than in those of cases. Residue V107 was substituted in NS3 cases but not in controls. However, these differences did not allow the definition of a specific NS3 profile related to HCC occurrence. The NS3 secondary structure B1-1 previously identified as potentially predictive of HCC was identified with a higher frequency in cases quasispecies (84.2%) than in controls (55.9%; P < 0.05). Our results suggest that there may be a relationship to fibrosis progression when diversity parameters are considered together with secondary structure profiles. Further investigations are required to determine the cellular interactions of HCV NS3 protease in the context of carcinogenesis.


Subject(s)
Carcinoma, Hepatocellular/virology , Fibrosis/virology , Hepacivirus/enzymology , Hepacivirus/genetics , Hepatitis C/virology , Liver Neoplasms/virology , Viral Nonstructural Proteins/genetics , Amino Acid Sequence , Base Sequence , Case-Control Studies , Disease Progression , Female , Humans , Middle Aged , Molecular Sequence Data , Phylogeny , Polymorphism, Genetic , Sequence Alignment
8.
Rev Epidemiol Sante Publique ; 54 Spec No 1: 1S23-1S31, 2006 Jul.
Article in French | MEDLINE | ID: mdl-17073127

ABSTRACT

BACKGROUND: Factors that influence the risk for HCV infection after occupational exposure to hepatitis C virus (HCV) have not yet been determined. The objective of this study was to assess potential risk factors for Hepatitis C seroconversion after occupational exposure to HCV. METHODS: We conducted a European matched case-control study from 01/01/1991 through 31/12/ 2002. Cases were Health Care Workers (HCWs) who were HCV seronegative at the time of exposure, sustained a documented exposure to HCV, and present documented HCV seroconversion temporally associated with the exposure. Controls-HCWs had a documented exposure to HCV, were HCV seronegative at the time of exposure, and remained so at least 6 months later. Controls were matched to cases for the center and the time period of the exposure occurrence. RESULTS: 60 cases and 204 controls were included. All cases were exposed to HCV-infected materials through percutaneous injuries. Those for whom information was available (61.6%) were exposed to viremic source patients. Multivariate conditional logistic regression analysis, in which HCV viral load was not introduced because of missing values, identified needle placed in the source patient's vein or artery (Odds Ratio [OR]=100.1; 95% Confidence Interval [CI]=7.3-1365.7), deep injury (OR=155.2; 95%CI=7.1-3417.2), and HCW's gender (M vs. F: OR=3.1; 95%CI=1.0-10.0) as risk factors for HCV infection. In univariate unmatched analysis the risk of HCV transmission was increased 11-fold (C195%=1.1-114.1) in HCWs exposed to sources with a viral load>6 log10 copies/mL when compared to sources with a HCV viral load<4 log10 copies/mL. CONCLUSION: The risk of HCV transmission after percutaneous exposure increases with a larger volume of blood, and, a higher titer of HCV in the source patient's blood. The role of HCW's gender need to be further investigated. The results of this study have important implications for counselling and follow-up of HCWs after exposure.


Subject(s)
Health Personnel , Hepatitis C/transmission , Infectious Disease Transmission, Patient-to-Professional , Occupational Exposure , Adult , Case-Control Studies , Confidence Intervals , Data Interpretation, Statistical , Europe , Female , Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepatitis C/immunology , Hepatitis C/virology , Hepatitis C Antibodies/analysis , Humans , Male , Middle Aged , Odds Ratio , RNA, Viral/analysis , Risk Factors , Surveys and Questionnaires , Time Factors , Viral Load
9.
Curr Top Microbiol Immunol ; 307: 151-71, 2006.
Article in English | MEDLINE | ID: mdl-16903225

ABSTRACT

Hepatitis D virus (HDV) is a satellite of hepatitis B virus (HBV) for transmission and propagation, and infects nearly 20 million people worldwide. The HDV genome is composed of a compact circular single-stranded negative RNA genome with extensive intramolecular complementarity. Along with epidemiological, geographic distribution and pathological patterns, the variability of HDV has been limited to three genotypes and two subtypes that have been characterized to date. Recently, extensive phylogenetic reconstructions based on the delta antigen gene and full-length genome sequence data, have shown a wide and probably ancient radiation of African lineages, suggesting that the genetic variability of HDV is much more complex than previously thought. Indeed, sequences previously affiliated with genotype IIb should now be considered as belonging to clade 4 (HDV-4) and African HDV sequences segregate within four additional clades: HDV-5, HDV-6, HDV-7 and HDV-8. These results bring the geographic distribution of HDV closer to the genetic variability of its helper HBV.


Subject(s)
Hepatitis Delta Virus/classification , Hepatitis Delta Virus/genetics , Amino Acid Sequence , Base Sequence , Genetic Variation , Genome, Viral , Genotype , Hepatitis B virus/genetics , Hepatitis delta Antigens/chemistry , Humans , Molecular Sequence Data , Phylogeny , RNA, Viral/chemistry
10.
J Viral Hepat ; 13(7): 474-81, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16792541

ABSTRACT

Little is known about the role of specific hepatitis C virus (HCV) CD8+ T cells in liver damage, especially for the progression of fibrosis, during the highly variable course of chronic C hepatitis. The aim of this study was to investigate the presence of HCV-specific CD8+ T cells in the liver of patients with chronic C hepatitis and to examine their clinical significance by relating the response to liver fibrosis and progression rate, serum viral load, serum aminotransferase levels, inflammatory activity and in situ characteristics of the intrahepatic infiltrate. Fifteen patients were prospectively included in the study. Intrahepatic lymphocytes were tested for interferon gamma (IFNg) production in response to HCV class I-restricted epitopic peptides using enzyme-linked immunospot analysis. Liver biopsy samples were evaluated for fibrosis, fibrosis progression rate, activity, and in situ number of CD8+ cytotoxic lymphocytes and apoptotic cells. An IFNg-specific CD8+ T-cell response was detected in the liver samples of 47% of patients which was significantly related to a lower stage of fibrosis (P = 0.02) and a lower progression rate of fibrosis (P = 0.01). It was neither related to the number of cytotoxic lymphocytes infiltrating the liver nor to hepatocyte apoptosis. In conclusion, our results indicate that the presence of HCV-specific IFNg-secreting T cells in the liver of patients with chronic C hepatitis is associated with low liver fibrosis and fibrosis progression rate, suggesting that these IFNg-secreting T cells might limit the progression of liver damage.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Hepatitis C, Chronic/immunology , Interferon-gamma/immunology , Liver Cirrhosis/immunology , Adult , Aged , CD8-Positive T-Lymphocytes/metabolism , Female , Hepatitis C, Chronic/enzymology , Hepatitis C, Chronic/pathology , Humans , Immunophenotyping , Interferon-gamma/metabolism , Liver/enzymology , Liver/immunology , Liver/metabolism , Liver Cirrhosis/enzymology , Liver Cirrhosis/pathology , Liver Cirrhosis/virology , Male , Middle Aged , Prospective Studies , Transaminases/blood
11.
J Viral Hepat ; 13(4): 278-88, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16611195

ABSTRACT

Lamivudine resistance has been described in subjects with chronic hepatitis B infections, associated with mutations in the viral polymerase gene. The objective of this study was to estimate the emergence rate of lamivudine-resistant viral strains and their consequences over a 2-year period. We evaluated 283 lamivudine-naïve subjects with chronic hepatitis B. Clinical and virological features were assessed at inclusion and every 6 months thereafter. Viral DNA was characterized using polymerase chain reaction (PCR)-based sequencing. Potential risk factors for the emergence of lamivudine resistance mutations were assessed using logistic regression analysis. The annualized incidence rate for viral polymerase mutations was 22%. The only independent risk factor identified was high viral load, at inclusion. Detectable viral DNA and elevated transaminases were more frequent in subjects harbouring mutant viral strains, and these underwent a lower rate of hepatitis B e seroconversion. All subjects responded favourably to treatment, with no difference in symptoms between the two groups. This prospective cohort study identified lamivudine-resistant mutations emerging in 22% of subjects, yearly, which were apparently not associated with clinical aggravation over the study period.


Subject(s)
Drug Resistance, Viral/genetics , Hepatitis B virus/genetics , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Lamivudine/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , DNA, Viral/chemistry , DNA, Viral/genetics , Female , France , Hepatitis B Antibodies/blood , Hepatitis B e Antigens/blood , Humans , Male , Middle Aged , Mutation , Polymerase Chain Reaction , Prospective Studies , Sequence Analysis, DNA , Statistics, Nonparametric
12.
Clin Infect Dis ; 41(10): 1423-30, 2005 Nov 15.
Article in English | MEDLINE | ID: mdl-16231252

ABSTRACT

BACKGROUND: Additional studies are required to identify risk factors for hepatitis C virus (HCV) transmission to health care workers after occupational exposure to HCV. METHODS: We conducted a matched case-control study in 5 European countries from 1 January 1991 through 31 December 2002. Case patients were health care workers who experienced seroconversion after percutaneous or mucocutaneous exposure to HCV. Control subjects were HCV-exposed health care workers who did not experience seroconversion and were matched with case patients for center and period of exposure. RESULTS: Sixty case patients and 204 control subjects were included in the study. All case patients were exposed to HCV-infected fluids through percutaneous injuries. The 37 case patients for whom information was available were exposed to viremic source patients. As risk factors for HCV infection, multivariate analysis identified needle placement in a source patient's vein or artery (odds ratio [OR], 100.1; 95% confidence interval [CI], 7.3-1365.7), deep injury (OR, 155.2; 95% CI, 7.1-3417.2), and sex of the health care worker (OR for male vs. female, 3.1; 95% CI, 1.0-10.0). Source patient HCV load was not introduced in the multivariate model. In unmatched univariate analysis, the risk of HCV transmission increased 11-fold for health care workers exposed to source patients with a viral load >6 log(10) copies/mL (95% CI, 1.1-114.1), compared with exposures to source patients with a viral load < or =4 log10 copies/mL. CONCLUSION: In this study, HCV occupational transmission was found to occur after percutaneous exposures. The risk of HCV transmission after percutaneous exposure increased with deep injuries and procedures involving hollow-bore needle placement in the source patient's vein or artery. These results highlight the need for widespread adoption of needlestick-prevention devices in health care settings, together with other preventive measures.


Subject(s)
Hepatitis C/transmission , Infectious Disease Transmission, Patient-to-Professional/statistics & numerical data , Occupational Exposure , Adult , Case-Control Studies , Europe , Female , Health Personnel , Humans , Male , Middle Aged , Multivariate Analysis , Needlestick Injuries , Risk Factors , Time Factors
13.
Pathol Biol (Paris) ; 53(8-9): 481-4, 2005.
Article in French | MEDLINE | ID: mdl-16084031

ABSTRACT

Transmission of tuberculosis within hospitals has been increasingly recognized as a hazard for patients and health care workers. A case of pulmonary tuberculosis was detected in September 2003 in a nursing auxiliary working at Avicenne's Hospital. This 49 year-old woman was considered infected since April 2003. During this 6 months period, she worked in 23 distinct hospital units and could have contaminated patients and hospital staffs. The epidemiological survey was comprised for 1735 individuals (701 hospital staffs and 1034 patients). It encompassed clinical, para-clinical investigations and bacteriological investigations. Furthermore, between January 2003 and September 2004, a systematic comparison of 62 Mycobacterium tuberculosis strains isolated in the hospital was conducted by spoligotyping, a molecular typing method in order to access an eventual transmission. The nursing auxiliary's strain clearly showed a distinct spoligotype from the other investigated strains. This spoligotype was unique in the international spoligotype database. In this large epidemiological survey of a case of suspected nosocomial of tuberculosis, spoligotyping appeared as an interesting, easy and rapid method of molecular typing. It allowed to demonstrate that the nursing auxiliary tuberculosis case was unrelated to the others cases of tuberculosis diagnosed in the hospital during this period.


Subject(s)
Cross Infection/microbiology , Mycobacterium tuberculosis/classification , Bacterial Typing Techniques , Cross Infection/transmission , Female , France , Humans , Middle Aged , Mycobacterium tuberculosis/isolation & purification , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/transmission
14.
Rheumatology (Oxford) ; 44(2): 247-50, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15546964

ABSTRACT

OBJECTIVES: Recently published findings suggested that antineutrophil cytoplasmic antibodies (ANCA), particularly those with a cytoplasmic (C-ANCA) labelling pattern and targeting proteinase 3 (anti-PR3), might be markers of tuberculosis (TB). This is a critical issue, because C-ANCA/anti-PR3 were considered to be a highly specific hallmark of Wegener's granulomatosis or microscopic polyangiitis and because TB may clinically mimic Wegener's granulomatosis. We therefore undertook a study with the aim of investigating further the prevalence and specificity of ANCA in TB. METHODS: We evaluated serum samples from 67 patients diagnosed with culture-proven TB and 10 previously untested control samples from patients known to be ANCA positive (four Wegener's granulomatosis and two microscopic polyangiitides) or negative. All 77 sera were screened for ANCA using commercially available indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA) for anti-PR3 and antimyeloperoxidase (MPO). IIF-positive and anti-PR3- and anti-MPO-negative sera were also tested for bactericidal/permeability-increasing protein, lactoferrin, elastase and cathepsin G specificities with commercially available ELISA. RESULTS: IIF detected ANCA in seven (10%) of the TB sera, including three C-ANCA and four atypical perinuclear-labelling ANCA. Only one IIF-negative specimen was anti-PR3 positive in ELISA. ANCA testing of the control sera yielded IIF and ELISA results concordant with previous findings, except for one borderline ELISA. CONCLUSION: Our results indicate that TB is associated with low ANCA seroprevalence and poor specificity, with no test serum showing combined C-ANCA/anti-PR3 activity. In a clinical setting of Wegener's granulomatosis/TB mimicry, such combined reactivity would seem to be more suggestive of Wegener's granulomatosis.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic/blood , Tuberculosis/immunology , Adult , Antibody Specificity , Comorbidity , Enzyme-Linked Immunosorbent Assay/methods , Female , Fluorescent Antibody Technique/methods , Humans , Male , Paris/epidemiology , Peroxidase/immunology , Seroepidemiologic Studies , Tuberculosis/blood , Tuberculosis/epidemiology
16.
J Virol Methods ; 109(2): 187-93, 2003 May.
Article in English | MEDLINE | ID: mdl-12711062

ABSTRACT

Assays to determine the hepatitis C virus (HCV) genotype have recently become useful for clinical decision making and may be suitable for epidemiological investigations, such as identifying HCV outbreaks in a given population. Molecular assays are the most common diagnostic tools for HCV genotyping. This study compares two genome typing assays, one, the Trugene 5'NC genotyping kit, uses the sequence of the 5' non-coding (5'NC) region and the other, a non-commercial assay, uses the non-structural 5b (NS5b) region. Serum samples from 203 chronically HCV-infected patients were tested. The 5'NC and the NS5b assays were both very effective in identifying the genotype (99 and 98.5%) and the results with the two methods were always concordant for the genotype. The NS5b analysis permitted the identification of the subtype in all samples, whereas the 5'NC region assay did not in 33% of samples. The NS5b analysis showed that one patient had a mixed infection with HCV subtypes 1a and 2c, while the 5'NC assay did not. It is concluded that phylogenetic analysis using both the 5'NC and the NS5b regions are reliable and convenient methods for HCV typing in clinical practice. But analysis of the NS5b region may be more useful for tracing the source of an HCV infection.


Subject(s)
5' Untranslated Regions/chemistry , Hepacivirus/classification , Viral Nonstructural Proteins/chemistry , Genotype , Hepacivirus/genetics , Phylogeny
18.
Rheumatology (Oxford) ; 41(3): 290-300, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11934966

ABSTRACT

OBJECTIVE: To describe a population of patients with symptomatic cryoglobulinaemia, comparing manifestations and outcome as a function of hepatitis C virus (HCV) status. PATIENTS AND METHODS: A retrospective study on 179 patients who tested positive for cryoglobulins, seen between 1978 and 1998 in an internal medicine department. RESULTS: Among 179 cryoglobulin-positive patients, only 49 (18 men, 31 women; mean age 59.96+/-12 yr) had clinical manifestations attributable to cryoglobulinaemia. Thirty-three had HCV infection, 20 had systemic autoimmune diseases, two had haematological diseases, one had human immunodeficiency virus and HCV co-infection, one had HCV and HBV co-infection and six had essential mixed cryoglobulinaemia. The clinical manifestations and cryoglobulin levels in HCV(+) and HCV(-) patients did not differ significantly. Only arthralgias and elevated transaminases were significantly more frequent in HCV(+) patients (P<0.02 and <0.05, respectively). Five-year survival rates were comparable for HCV(+) and HCV(-) patients. Eight patients died (six HCV(+), two HCV(-)), with a median time between diagnosis and death of 38.7 months. CONCLUSION: Clinical manifestations of cryoglobulinaemia, except arthralgias, were comparable for HCV(+) and HCV(-) patients. When systemic manifestations are present, the prognosis is poor despite intensive or prolonged therapy.


Subject(s)
Cryoglobulinemia/complications , Hepatitis C, Chronic/complications , Cryoglobulinemia/blood , Cryoglobulinemia/virology , Cryoglobulins/analysis , Drug Therapy, Combination , Enzyme-Linked Immunosorbent Assay , Female , Glucocorticoids/therapeutic use , Hepacivirus/genetics , Hepacivirus/immunology , Hepacivirus/isolation & purification , Hepatitis Antibodies/blood , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/drug therapy , Humans , Interferon-alpha/therapeutic use , Male , Middle Aged , RNA, Viral/analysis , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate , Treatment Outcome
20.
Rev Mal Respir ; 18(3): 247-55, 2001 Jun.
Article in French | MEDLINE | ID: mdl-11468586

ABSTRACT

A role for viruses in the development or course of the main idiopathic chronic infiltrative lung disease has been suggested for a long time. Viruses that have usually been incriminated in cryptogenic fibrosing alveolitis are hepatitis C virus, whose role has not been accurately proven, and latent viruses including Epstein-Barr virus and adenovirus. These latent viruses might be re-activated in the lung of patients immunocompromised by treatments and might be accountable for disease progression. However, published studies have been very conflicting and the only clinical trial testing ribavirin has failed to demonstrate a beneficial effect. In sarcoidosis, the responsibility of human herpesvirus 6 and 8 and retroviruses has not been proven. Finally, data in the literature do not support a link between Langerhans cell histiocytosis and human herpesvirus 6 and 8. These viruses may act by several mechanisms: viral proteins may be antigens driving an appropriate immune response; they may also behave as transactivating factors to control the expression of various genes involved in immune response, cell growth or synthesis of matrix proteins.


Subject(s)
Pulmonary Fibrosis/virology , Sarcoidosis/virology , Virus Diseases/complications , Cell Division , Chronic Disease , Disease Progression , Gene Expression Regulation , Humans , Immunocompromised Host , Pulmonary Fibrosis/pathology , Sarcoidosis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...